Form 4: IN8BIO CFO McCall Reports Acquisition and Disposal of Securities Following Warrant Amendment
SEC Form 4 Filing
Chief Financial Officer Patrick McCall reports changes in beneficial ownership of IN8BIO, INC. securities, including the acquisition and disposal of common stock and warrants, following an amendment to existing warrants.
Summary
- On October 4, 2024, Patrick McCall, the CFO of IN8BIO, INC., reported transactions involving the company's securities.
- McCall acquired 25,316 shares of common stock as part of a unit purchase at $0.395 per unit, with each unit including one share of common stock and one Series C warrant.
- He also disposed of 20,492 Series A warrants with an exercise price of $1.25 and acquired 20,492 Series A warrants with a reduced exercise price of $0.45 due to an amendment.
- The expiration date of the Series A warrants was extended from June 13, 2025, to October 4, 2025.
- Additionally, McCall acquired 25,316 Series C warrants with an exercise price of $0.27.
- These transactions resulted in McCall owning 52,071 shares of common stock and 20,492 Series A warrants and 25,316 Series C warrants.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing of insider transactions. The warrant amendment could be seen as slightly positive, but overall, it's a standard disclosure.
Positives
- The warrant amendment lowers the exercise price of the Series A warrants from $1.25 to $0.45, potentially making them more attractive to exercise.
- The extension of the Series A warrant expiration date to October 4, 2025, gives McCall more time to potentially benefit from the warrants.
- McCall's purchase of 25,316 Issuer Units shows confidence in the company.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and alignment with shareholder interests.
Stakeholder Impact
- Shareholders may be interested in the CFO's transactions as an indicator of management's confidence in the company.
- The warrant amendment could potentially dilute existing shareholders if the warrants are exercised.
Key Dates
| Date | Description |
|---|---|
| 12/13/2023 | Original grant date of Series A warrants with an exercise price of $1.25 and expiration date of June 13, 2025. |
| 06/13/2025 | Original expiration date of Series A warrants before amendment. |
| 10/04/2024 | Date of transaction: acquisition and disposal of securities, warrant amendment, and purchase of Issuer Units. |
| 10/04/2025 | New expiration date of Series A warrants after amendment. |
| 10/04/2027 | Expiration date of Series C warrants. |
| 10/08/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.